Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05037487 · ClinicalTrials.gov registry record · Phase 1

Evaluation of Smoked THC and CBD in Men and Women

A Phase 1 study of Drug Abuse and Impairment, sponsored by University of California, Los Angeles.

Completed
Registry status
Phase 1
Development phase
19
Enrollment target
1
Study location

NCT05037487 is a Phase 1 study of Drug Abuse and Impairment that has completed, run by University of California, Los Angeles. The registered enrollment target is 19 participants, below the 325-participant average among 21 other Drug Abuse trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05037487, a Phase 1 study of Drug Abuse and Impairment, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
Phase 1
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.

Interventions

  • DRUG Placebo Cannabis
  • DRUG 20 mg CBD Cannabis
  • DRUG 20 mg CBD + 20 mg THC Cannabis
  • DRUG 20 mg THC Cannabis

Study Locations (1)

California

  • University of California, Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2022-09-01
Est. Completion 2025-06-08
Phase Phase 1

What the Registry Record Tells You About NCT05037487

The ClinicalTrials.gov registry entry for NCT05037487 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 325-participant average among 21 other Drug Abuse trials with a reported enrollment target (94% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Drug Abuse appearing as the primary indexed condition, and to 4 interventions - of which Placebo Cannabis is the first listed.

NCT05037487 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05037487 about?

NCT05037487 is a clinical study titled "Evaluation of Smoked THC and CBD in Men and Women". The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.

What is the current status of trial NCT05037487?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2022-09-01. Estimated completion is 2025-06-08.

What conditions does trial NCT05037487 study?

This clinical trial studies the following conditions: Drug Abuse, Impairment, Intoxication by Drug.

What interventions are being tested in trial NCT05037487?

The interventions under investigation include: Placebo Cannabis (DRUG), 20 mg CBD Cannabis (DRUG), 20 mg CBD + 20 mg THC Cannabis (DRUG), 20 mg THC Cannabis (DRUG).

Who is sponsoring clinical trial NCT05037487?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05037487 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Drug Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.